174.06
0.20%
+0.35
After Hours:
174.06
Overview
News
Price History
Option Chain
Financials
Why ZTS Down?
Discussions
Forecast
Dividend History
Zoetis Inc stock is currently priced at $174.06, with a 24-hour trading volume of 1.92M.
It has seen a +0.20% increased in the last 24 hours and a +14.56% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $173.7 pivot point. If it approaches the $174.8 resistance level, significant changes may occur.
Previous Close:
$173.71
Open:
$174.05
24h Volume:
1.92M
Market Cap:
$79.42B
Revenue:
$8.73B
Net Income/Loss:
$2.39B
P/E Ratio:
35.38
EPS:
4.92
Net Cash Flow:
$1.75B
1W Performance:
+2.97%
1M Performance:
+14.56%
6M Performance:
-0.42%
1Y Performance:
-2.73%
Zoetis Inc Stock (ZTS) Company Profile
Zoetis Inc Stock (ZTS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-12-24 | Reiterated | Stifel | Buy |
Dec-19-23 | Resumed | Jefferies | Buy |
Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
Sep-06-23 | Initiated | HSBC Securities | Buy |
Jul-12-22 | Initiated | Piper Sandler | Overweight |
Nov-18-21 | Initiated | Morgan Stanley | Overweight |
Aug-05-21 | Resumed | Credit Suisse | Outperform |
Jul-16-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
Mar-08-21 | Upgrade | BofA Securities | Neutral → Buy |
Mar-08-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
Sep-21-20 | Initiated | Atlantic Equities | Overweight |
Aug-14-20 | Upgrade | Edward Jones | Hold → Buy |
Aug-12-20 | Downgrade | Gabelli & Co | Buy → Hold |
May-27-20 | Initiated | Jefferies | Buy |
Jan-10-20 | Initiated | Raymond James | Mkt Perform |
Sep-09-19 | Initiated | Goldman | Buy |
Jul-01-19 | Downgrade | BofA/Merrill | Buy → Neutral |
Jun-11-19 | Initiated | Barclays | Overweight |
May-23-19 | Initiated | Guggenheim | Buy |
May-03-19 | Downgrade | Gabelli & Co | Buy → Hold |
Mar-20-19 | Initiated | SunTrust | Hold |
Mar-04-19 | Upgrade | Stifel | Hold → Buy |
Jan-23-19 | Initiated | UBS | Neutral |
Oct-15-18 | Upgrade | JP Morgan | Neutral → Overweight |
Aug-22-18 | Downgrade | Stifel | Buy → Hold |
Aug-03-18 | Reiterated | Stifel | Buy |
Apr-19-18 | Reiterated | Citigroup | Buy |
Mar-19-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Feb-16-18 | Reiterated | Stifel | Buy |
Jan-04-18 | Upgrade | Citigroup | Neutral → Buy |
View All
Zoetis Inc Stock (ZTS) Latest News
Montrusco Bolton Investments Inc. Has $65.18 Million Stock Position in Zoetis Inc. (NYSE:ZTS) - MarketBeat
MarketBeat
MSN - MSN
MSN
Fiera Capital Corp Grows Position in Zoetis Inc. (NYSE:ZTS) - MarketBeat
MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zoetis Inc. - ZTS - PR Newswire
PR Newswire
10,643 Shares in Zoetis Inc. (NYSE:ZTS) Purchased by Farrow Financial Inc. - MarketBeat
MarketBeat
Is Zoetis (ZTS) Stock Outpacing Its Medical Peers This Year? - Yahoo New Zealand News
Yahoo New Zealand News
Zoetis Inc Stock (ZTS) Financials Data
Zoetis Inc (ZTS) Revenue 2024
ZTS reported a revenue (TTM) of $8.73 billion for the quarter ending March 31, 2024, a +7.91% rise year-over-year.
Zoetis Inc (ZTS) Net Income 2024
ZTS net income (TTM) was $2.39 billion for the quarter ending March 31, 2024, a +15.45% increase year-over-year.
Zoetis Inc (ZTS) Cash Flow 2024
ZTS recorded a free cash flow (TTM) of $1.75 billion for the quarter ending March 31, 2024, a +20.03% increase year-over-year.
Zoetis Inc (ZTS) Earnings per Share 2024
ZTS earnings per share (TTM) was $5.19 for the quarter ending March 31, 2024, a +17.16% growth year-over-year.
Zoetis Inc Stock (ZTS) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Lagano Roxanne | Executive Vice President |
Apr 18 '24 |
Sale |
151.17 |
923 |
139,530 |
14,800 |
Lagano Roxanne | Executive Vice President |
Mar 18 '24 |
Sale |
173.33 |
923 |
159,984 |
15,723 |
Reed Willie M | Director |
Mar 11 '24 |
Sale |
182.68 |
1,370 |
250,265 |
9,994 |
PECK KRISTIN C | Chief Executive Officer |
Feb 20 '24 |
Option Exercise |
46.09 |
13,000 |
599,170 |
92,366 |
PECK KRISTIN C | Chief Executive Officer |
Feb 20 '24 |
Sale |
187.20 |
13,000 |
2,433,636 |
79,366 |
Lagano Roxanne | Executive Vice President |
Feb 20 '24 |
Sale |
187.30 |
923 |
172,878 |
16,646 |
Lagano Roxanne | Executive Vice President |
Feb 13 '24 |
Sale |
186.86 |
2,848 |
532,177 |
17,569 |
Lagano Roxanne | Executive Vice President |
Feb 12 '24 |
Sale |
197.74 |
363 |
71,780 |
20,417 |
Lagano Roxanne | Executive Vice President |
Jan 18 '24 |
Sale |
191.43 |
923 |
176,690 |
17,569 |
Lagano Roxanne | Executive Vice President |
Dec 18 '23 |
Sale |
198.14 |
923 |
182,883 |
18,492 |
About Zoetis Inc
Zoetis Inc. discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides medicated feed additives that offer medicines to livestock; and other pharmaceutical products, which comprise allergy and dermatology, pain and sedation, antiemetic, reproductive, and oncology products. In addition, the company offers other product categories, including nutritionals and agribusiness services, as well as products and services in complementary areas, such as biodevices, diagnostics, and genetics. It markets its products to veterinarians, livestock producers, and people who raise and care for farm and companion animals through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Cap:
|
Volume (24h):